Oxford to study anti-inflammatory drug Humira as potential COVID-19 treatment

By Kate Kelland and Josephine Mason

LONDON ( Reuters)-The University of Oxford reported on Wednesday it was planned to research the effectiveness of COVID-19 in the top-selling generic drug, adalimumab, the most recent attempt to utilize current pharmaceutical ingredients for future coronoviral therapy.

Adalimumab is a kind of anti-inflammatory medication known as anti-tumor necrosis factor (anti-TNF), which is marketed under the brand name Humira by AbbVie.

Latest findings suggest that patients who undergo anti-TNF therapies with COVID-19 are less likely to be authorized to hospital in inflammatory bowel disease or inflammatory arthritis, according to Oxford.

The Oxford examination, known as the AVID-CC trial, can handle individuals in the population in particular in treatment centers, according to the university.

Up to 750 community-based patients in Britain would be accepted.

The care with Humira involves rheumatoid arthritis, Crohn's disease, ulcerative colitis, and psoriasis.

Oxford said it will be cost efficient and affordable to offer biosimilar copies of the drug if the study were successful.

Novartis makes Hyrimoz one of the choices.

Some drugs, including Gilead's remdesivir as well as a generic steroid dexamethasone have been detected for patients affected by COVID-19.

Other anti-inflammatory medications for COVID-19 have also been reported by researchers.

The overaction of the immune system known as a cytokine storm and medicines that suppress certain elements of the immune system can help to avoid an expeditious worsening of the symptoms is believed to have caused severe infections.

However, successful procedures for those not accepted into the facility have not yet been introduced.

The first surge of COVID-19 in the United Kingdom and elsewhere affected nursing homes in particular.

Humira may support certain seniors, certain of those who are among the most disadvantaged, if it worked against COVID-19 at a period when policymakers are trying to avoid the pandemic.

The Oxford research is sponsored by COVID-19 The Wellcom public health organization Therapeutics Acceleration project, Bill and Melinda Gates Foundation and Mastercard.

(Josephine and Kate Mason's study in London and John Miller's study in Zurich; Mark Heinrich's article)

Advertisement